$16.32
-1.00%
2026-09-04 13:10:40 EDT-$0.17
헬스케어
의료 - 기기
NASDAQ
활발히 거래 중
Delcath Systems, Inc.는 미국과 유럽에서 활동하는 중재적 종양학 기업으로, 원발성 및 전이성 간암의 치료제 개발에 전념하고 있습니다. 이 회사의 주요 연구용 제품은 ...
Delcath Systems, Inc.는 미국과 유럽에서 활동하는 중재적 종양학 기업으로, 원발성 및 전이성 간암의 치료제 개발에 전념하고 있습니다. 이 회사의 주요 연구용 제품은 ...
The HEPZATO KIT is a proprietary, investigational hepatic delivery system (HDS) that enables the delivery of high-dose chemotherapy (melphalan) directly to the liver. By isolating the liver from the systemic circulatory system, the kit allows for a significantly higher concentration of the therapeutic agent to reach liver tumors while minimizing systemic exposure and reducing drug-related side effects to the rest of the body.
가격대: Not publicly disclosed
페인 포인트: Limited treatment options for liver metastases; systemic toxicity associated with conventional chemotherapy.
솔루션: Vascular isolation of the liver, focused delivery of chemotherapy, and filtration of excess drug to improve clinical outcomes.
대상 사용자: Oncology hospitals, interventional radiology centers, and specialized cancer treatment facilities treating patients with metastatic uveal melanoma.
The CHEMOSAT Hepatic Delivery System provides a platform for administering high-dose chemotherapy to the liver via percutaneous hepatic perfusion (PHP). It is marketed as a medical device in Europe, empowering medical centers to manage a diverse array of liver cancer conditions by facilitating targeted drug delivery while filtering the blood to reduce systemic toxicity.
가격대: Not publicly disclosed
페인 포인트: Lack of effective treatment for complex, primary and secondary liver cancers; high systemic side effects of standard oncology therapies.
솔루션: Minimally invasive, localized drug delivery to the liver and blood filtration, allowing for higher therapeutic efficacy.
대상 사용자: European medical centers, interventional oncologists, and liver cancer specialty clinics.